Bioorthogonal Nanoclear System: A Reproducible, Falsifiable Quantitative Systems-Pharmacology Framework for Multi-Modal Nanotherapeutic Reversal of Sepsis Pathologies

Purpose: Sepsis, a dysregulated host response to infection, causes an estimated 49 million cases and 11 million deaths annually, accounting for close to one in five deaths worldwide. Over a century of single-target immunomodulatory trials has failed to reduce mortality below 20 to 30%, largely because of endotype heterogeneity, a narrow therapeutic window, and compensatory anti-inflammatory response syndrome. This Perspective develops the Bioorthogonal Nanoclear (BON) system, a hybrid, pH-responsive PLGA nanoplatform integrating pathogen/damage-associated molecular pattern (PAMP/DAMP) sequestration, interleukin-10 (IL-10)-mediated immunomodulation, and sphingosine-1-phosphate (S1P)-mediated endothelial stabilization, as a fully computable, falsifiable conceptual framework rather than a set of asserted performance claims.Methods: A reproducible quantitative systems pharmacology (QSP) core, implemented in pure NumPy/SciPy (fixed seed, bit-identical across runs), couples (i) an equilibrium (Langmuir) PAMP/DAMP sequestration model parameterized by literature dissociation constants for Pep19-2.5 to LPS (Kd approximately 1 nM) and low-molecular-weight heparin to HMGB1 (Kd approximately 0.38 nM), (ii) a pH-triggered Peppas release model (n equals 0.43) calibrated to the stated 80% cumulative release at 12 hours at pH 6.5 to 6.9, (iii) a two-compartment pharmacokinetic model, and (iv) a coupled LPS to NF-kB to IL-6 ordinary differential equation (ODE) cascade in which sequestration and IL-10-arm activity act as explicit, mechanistically coupled inputs.Results: At literature-anchored base parameters, the model predicts 70.7% LPS and 48.0% HMGB1 sequestration; 800-sample Monte Carlo propagation of parameter uncertainty gives 70.0% (SD 16.9, 95% CI 27.8 to 93.0%) and 42.7% (SD 19.5, 95% CI 10.7 to 83.9%) respectively, with P(LPS sequestration greater than 60%) equals 74.6%. A 2 by 2 factorial (sequestration by IL-10 arm) predicts an 88.1% peak IL-6 reduction for the full BON system, sub-additive relative to the two single-arm contributions (synergy index minus 32.1 percentage points), indicating mechanistic overlap rather than synergy under the modeled assumptions, an explicit, falsifiable, and previously unstated model prediction. A composite therapeutic-index-to-survival-benefit surrogate gives a Monte Carlo mean of 39.8% (SD 10.3, 95% CI 12.2 to 50.6%), with 75.6% of samples falling inside the literature-comparator range of 30 to 50% survival improvement reported for related single-target nanotherapeutics (Table 2). A hand-implemented Saltelli-sampling and Jansen (1999) Sobol total-effect analysis (N equals 200, 10 parameters) identifies the fraction of surface ligand sterically and kinetically accessible for productive binding as the single dominant source of output uncertainty (ST equals 0.61), ahead of administered dose (ST equals 0.45) and ligand surface density (ST equals 0.09), a quantitative, falsifiable prioritization for the experimental roadmap.Conclusion: The BON system is presented as a mechanistically transparent, fully reproducible, and falsifiable multi-modal nanotherapeutic hypothesis for sepsis. As a conceptual framework with no wet-laboratory data of its own, its central claims, sequestration efficiency, cytokine attenuation, and the specific numerical predictions above, are explicitly stated as testable and are accompanied by pre-registered rejection criteria (Section 10). The dominant sensitivity of the model to ligand accessibility identifies protein-corona engineering and multivalent-avidity characterization as the highest-priority items for preclinical validation.